8-K: Inhibrx Biosciences Presents Promising Clinical Data

Inhibrx Biosciences shared updated corporate information, focusing on positive clinical trial results for INBRX-106 and INBRX-109, and outlining future development milestones.

Summary

• Inhibrx Biosciences posted an updated corporate presentation on September 28, 2026, detailing progress on its investigational drug candidates.
• The presentation highlights positive clinical data for INBRX-106, a hexavalent OX40 agonist, showing superior efficacy when combined with pembrolizumab in head and neck squamous cell carcinoma (HNSCC), particularly in HPV+ patients.
• Data for INBRX-109, a tetravalent DR5 agonist, demonstrates a significant improvement in progression-free survival (PFS) in chondrosarcoma patients, meeting its primary endpoint.
• The company also presented encouraging preliminary data for INBRX-109 in combination with FOLFIRI for colorectal cancer and INBRX-106 in peri-operative non-small cell lung cancer (NSCLC).
• Key financial highlights as of August 6, 2026, include $219.5 million in cash and cash equivalents and 14.7 million common shares outstanding.
• Near-term milestones include potential approval and launch of ozekibart (INBRX-109) for chondrosarcoma in late 2026, and planned FDA meetings for INBRX-109 in colorectal cancer.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a positive update, highlighting significant clinical trial progress and promising data for key drug candidates, suggesting strong future potential.

Positives

• INBRX-106 demonstrated a significantly higher objective response rate (ORR) of 80% vs. 33% and a 90% PFS6 rate vs. 33% in HPV+ HNSCC patients when combined with pembrolizumab, compared to pembrolizumab alone.
• INBRX-109 met its primary endpoint in a chondrosarcoma registrational trial, more than doubling median PFS to 5.52 months from 2.66 months (52% reduction in risk of progression or death).
• The combination of INBRX-106 and pembrolizumab showed a 48.3% ORR in first-line recurrent/metastatic HNSCC, compared to 26.5% for pembrolizumab alone.
• Preliminary data for INBRX-109 in 3-4L colorectal cancer showed an 87% disease control rate and a 20% ORR.
• INBRX-106 showed superior T-cell proliferation (up to 15-fold increase) and activation (up to 4-fold increase) compared to pembrolizumab alone.
• The company has $219.5 million in cash and cash equivalents as of August 6, 2026.
• Orphan designations (FDA & EMA) and Fast Track designation (FDA) have been granted for ozekibart (INBRX-109) in chondrosarcoma.

Negatives

• While INBRX-106 showed strong results in HPV+ HNSCC, the ORR in HPV-negative patients was 31.6% with the combination versus 24.0% for pembrolizumab alone, indicating a less pronounced benefit in this subgroup.
• The most frequent treatment-related adverse events for INBRX-106 + Pembro included rash, fatigue, and diarrhea, with Grade 3 AEs occurring in 48.4% of the combination arm compared to 11.8% in the pembrolizumab-only arm.
• For INBRX-109 in chondrosarcoma, Grade 3 adverse events occurred in 39.0% of patients on ozekibart compared to 25.4% on placebo, and serious adverse events were reported in 27.9% vs. 17.9% respectively.
• Treatment discontinuation due to adverse events was higher in the INBRX-106 + Pembro arm (35.5%) compared to the pembrolizumab alone arm (14.7%) in the HexAgon-HN study.

Risks

• The presentation contains forward-looking statements regarding business strategy, product development, clinical trials, regulatory filings, and financial performance, which are subject to significant known and unknown risks, uncertainties, and other factors that could cause actual results to differ materially.
• The assumptions and estimates underlying projected financial information are inherently uncertain and subject to a wide variety of significant business, economic, competitive, and other risks and uncertainties.
• Investigational product candidates discussed have not been approved or licensed by regulatory authorities and are not commercially available.
• The company may not achieve its plans, intentions, or expectations disclosed in forward-looking statements, and undue reliance should not be placed on them.
• The efficacy and safety of INBRX-106 and INBRX-109 in ongoing and future trials may not be representative of later trials or commercial use.
• The market size and growth potential for product candidates are estimates and subject to significant uncertainty.
• Cross-trial comparisons of safety data (e.g., HexAgon-HN vs. KEYNOTE-048) are limited due to differences in study designs, populations, regimens, and follow-up.

Future Outlook

The company anticipates potential approval and commercial launch of ozekibart (INBRX-109) for chondrosarcoma in the second half of 2026. Plans include meeting with the FDA to discuss registrational trial design for INBRX-109 in colorectal cancer and potential accelerated pathways. Further milestones include initiating the Phase 3 portion of the HexAgon study for INBRX-106 and presenting interim data for INBRX-109 in CRC and INBRX-106 in NSCLC in 2027.

Management Comments

• The company's mission is to discover & develop effective biologic treatments for people with life-threatening conditions.
• INBRX-106 is designed to supercharge the immune system against tumors and reverse immune suppression, complementing checkpoint inhibitors.
• The HexAgon study design aims for a seamless Phase 2/3 approach, representing the fastest path to market.
• The HPV+ HNSCC data and over 20 years of academic research support the strong mechanistic rationale of INBRX-106 combined with cancer vaccines.
• Ozekibart (INBRX-109) has demonstrated unprecedented data in chondrosarcoma, meeting its primary endpoint with a significant reduction in the risk of disease progression or death.

Industry Context

StockSavvy.ai notes that Inhibrx's presentation aligns with the growing trend in oncology towards combination therapies and novel mechanisms of action, such as OX40 agonism and DR5 agonism, to overcome resistance to existing treatments like checkpoint inhibitors. The focus on specific patient populations (e.g., HPV+ HNSCC) and rare diseases (chondrosarcoma) reflects a strategic approach to address unmet needs and potentially secure expedited regulatory pathways.

Comparison to Industry Standards

• In 1L R/M HNSCC, the combination of INBRX-106 + Pembro achieved an ORR of 48.3%, significantly higher than the 26.5% ORR seen with Pembro monotherapy in the KEYNOTE-048 study.
• For HPV+ HNSCC, the INBRX-106 + Pembro combination showed an 80% ORR, compared to 33.3% for Pembro monotherapy in KEYNOTE-048.
• In chondrosarcoma, Ozekibart (INBRX-109) demonstrated a median PFS of 5.52 months, more than doubling the 2.66 months seen with placebo, and a 52% reduction in the risk of progression or death, outperforming historical benchmarks for this rare cancer.
• In 3-4L colorectal cancer, the preliminary ORR of 20% for Ozekibart + FOLFIRI benchmarks favorably against other late-line therapies like Lonsurf + bevacizumab (SUNLIGHT, 6.1% ORR), regorafenib (CORRECT, 1.0% ORR), and fruquintinib (FRESCO-2, 1.5% ORR).

Stakeholder Impact

• Shareholders may see increased confidence due to positive clinical data and potential for future product approvals and revenue.
• Patients with advanced HNSCC, particularly HPV+ subtypes, may benefit from a more effective treatment option.
• Patients with chondrosarcoma may soon have access to a new therapy that significantly improves progression-free survival.
• The broader oncology community and physicians may consider new treatment paradigms involving OX40 agonism and DR5 agonism in combination therapies.

Next Steps

• Plan to meet with FDA to discuss 1L CRC registrational trial design and potential accelerated regulatory pathway for 4L CRC (Ozekibart INBRX-109).
• Potential approval and first commercial launch of ozekibart (INBRX-109) for chondrosarcoma in 2H 2026.
• Initiation of Phase 3 portion of HexAgon study for INBRX-106.
• Interim data from combination cohorts in CRC (Ozekibart INBRX-109) in 1H 2027.
• Interim data from perioperative NSCLC study (INBRX-106) in 1H 2027.
• Expansion of Phase 2 portion of HexAgon study for INBRX-106.
• Data from expansion of Phase 2 HexAgon study for INBRX-106.
• Expansion of Phase 2 HexAgon-HN with potential for accelerated approval in HPV+ by end of 2028/early 2029.

Key Dates

Recommendation

The filing presents highly positive clinical data for two key drug candidates, INBRX-106 and INBRX-109, demonstrating significant efficacy improvements in challenging cancer indications like HNSCC and chondrosarcoma. The data not only meets but exceeds expectations, with clear potential for accelerated regulatory pathways and market entry. The strong cash position provides runway for continued development. These factors collectively suggest a strong potential for significant value creation, warranting a strong buy recommendation.

Keywords

INBRX-106, INBRX-109, OX40 agonist, DR5 agonist, HNSCC, chondrosarcoma, clinical trials, oncology